NASDAQ:DEPO - Depomed Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$7.30
+0.30 (1.20%)
Get New Depomed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DEPO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DEPO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Depomed in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $7.30.
N/A
The current consensus among 0 contributing investment analysts is to n/a stock in Depomed. This rating has held steady since July 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/8/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/7/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/6/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/1/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/8/2018Royal Bank of CanadaSet Price TargetHold$8.00High
i
Rating by Randall Stanicky at Royal Bank of Canada
7/9/2018Janney Montgomery ScottUpgradeNeutral ➝ Buy$7.00 ➝ $10.00Medium
i
3/23/2018MizuhoReiterated RatingBuy$9.00High
i
3/2/2018Roth CapitalSet Price TargetBuy$10.00Medium
i
Rating by Scott Henry at Roth Capital
3/1/2018Piper Jaffray CompaniesReiterated RatingHold$8.00Medium
i
Rating by David Amsellem at Piper Jaffray Companies
12/7/2017Royal Bank of CanadaSet Price TargetHold$9.00Medium
i
Rating by Randall Stanicky at Royal Bank of Canada
12/7/2017Piper Jaffray CompaniesReiterated RatingHold$9.00High
i
Rating by David Amsellem at Piper Jaffray Companies
12/5/2017MizuhoUpgradeNeutral ➝ Buy$9.00High
i
11/10/2017Piper Jaffray CompaniesReiterated RatingHold$5.00N/A
i
Rating by David Amsellem at Piper Jaffray Companies
11/10/2017UBS GroupBoost Price TargetNeutral$6.00 ➝ $7.00N/A
i
11/9/2017Morgan StanleyUpgradeUnderweight ➝ Equal WeightN/A
i
11/8/2017Royal Bank of CanadaLower Price TargetSector Perform$8.00 ➝ $6.00N/A
i
Rating by Randall Stanicky at Royal Bank of Canada
10/27/2017Royal Bank of CanadaSet Price TargetHold$8.00N/A
i
Rating by Randall Stanicky at Royal Bank of Canada
10/20/2017Royal Bank of CanadaSet Price TargetHold$10.00N/A
i
Rating by Randall Stanicky at Royal Bank of Canada
10/15/2017Piper Jaffray CompaniesSet Price TargetHold$9.00N/A
i
Rating by David Amsellem at Piper Jaffray Companies
10/13/2017MizuhoReiterated RatingNeutral$11.00 ➝ $6.00N/A
i
9/10/2017Piper Jaffray CompaniesReiterated RatingHold$9.00High
i
8/9/2017Piper Jaffray CompaniesReiterated RatingNeutral$10.00 ➝ $9.00Medium
i
8/8/2017Morgan StanleyDowngradeEqual Weight ➝ Underweight$12.00 ➝ $5.00High
i
8/8/2017Royal Bank of CanadaLower Price TargetSector Perform ➝ Sector Perform$13.00 ➝ $10.00High
i
Rating by Randall Stanicky at Royal Bank of Canada
8/8/2017Janney Montgomery ScottDowngradeBuy ➝ Neutral$18.00 ➝ $8.00High
i
7/16/2017Royal Bank of CanadaSet Price TargetHold$13.00Low
i
Rating by Randall Stanicky at Royal Bank of Canada
6/13/2017Royal Bank of CanadaReiterated RatingHold$13.00Low
i
Rating by Randall Stanicky at Royal Bank of Canada
5/25/2017MizuhoLower Price TargetNeutral$13.00 ➝ $11.00Medium
i
5/15/2017Cantor FitzgeraldSet Price TargetHold$14.00Medium
i
Rating by Chiara Russo at Cantor Fitzgerald
5/10/2017Royal Bank of CanadaLower Price TargetSector Perform$19.00 ➝ $13.00Low
i
Rating by Randall Stanicky at Royal Bank of Canada
5/10/2017Piper Jaffray CompaniesUpgradeUnderweight ➝ Neutral$11.00 ➝ $10.00High
i
Rating by David Amsellem at Piper Jaffray Companies
4/11/2017Janney Montgomery ScottReiterated RatingBuy$26.00Low
i
3/30/2017JMP SecuritiesReiterated RatingOutperform$30.00 ➝ $16.00High
i
3/29/2017Janney Montgomery ScottReiterated RatingBuy$26.00High
i
3/29/2017Royal Bank of CanadaLower Price TargetSector Perform ➝ Sector Perform$22.00 ➝ $19.00High
i
Rating by Randall Stanicky at Royal Bank of Canada
3/29/2017Cantor FitzgeraldReiterated RatingHold$19.00High
i
Rating by Chiara Russo at Cantor Fitzgerald
3/29/2017MizuhoLower Price TargetNeutral ➝ Neutral$16.00 ➝ $13.00Low
i
3/25/2017Royal Bank of CanadaSet Price TargetHold$22.00Low
i
Rating by Randall Stanicky at Royal Bank of Canada
3/1/2017Cantor FitzgeraldSet Price TargetHold$23.00 ➝ $19.00N/A
i
Rating by Chiara Russo at Cantor Fitzgerald
2/27/2017Janney Montgomery ScottReiterated RatingBuyN/A
i
2/23/2017Royal Bank of CanadaReiterated RatingSector Perform$22.00N/A
i
2/20/2017MizuhoDowngradeBuy ➝ NeutralN/A
i
2/18/2017Roth CapitalSet Price TargetBuy$24.00N/A
i
Rating by Scott Henry at Roth Capital
2/14/2017MizuhoDowngradeBuy ➝ Neutral$24.00 ➝ $17.00N/A
i
1/11/2017Cantor FitzgeraldSet Price TargetHold$23.00N/A
i
Rating by Chiara Russo at Cantor Fitzgerald
12/12/2016Roth CapitalSet Price TargetBuy$27.00N/A
i
Rating by Scott Henry at Roth Capital
12/12/2016Piper Jaffray CompaniesDowngradeNeutral ➝ Underweight$17.00 ➝ $14.00N/A
i
Rating by David Amsellem at Piper Jaffray Companies
12/4/2016Roth CapitalSet Price TargetBuy$27.00N/A
i
Rating by Scott Henry at Roth Capital
11/28/2016Roth CapitalSet Price TargetBuy$27.00N/A
i
Rating by Scott Henry at Roth Capital
11/9/2016MizuhoUpgradeNeutral ➝ Buy$27.00 ➝ $24.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
11/8/2016SVB LeerinkSet Price TargetBuy$22.00N/A
i
Rating by Jason Gerberry at SVB Leerink LLC
11/8/2016MizuhoReiterated RatingHold$27.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
11/8/2016Cantor FitzgeraldDowngradeBuy ➝ Hold$25.00 ➝ $23.00N/A
i
Rating by chiara russo at Cantor Fitzgerald
10/30/2016Roth CapitalSet Price TargetBuy$28.00N/A
i
Rating by Scott Henry at Roth Capital
10/21/2016Roth CapitalSet Price TargetBuy$28.00N/A
i
Rating by Scott Henry at Roth Capital
10/18/2016MizuhoReiterated RatingHold$27.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
10/17/2016Janney Montgomery ScottReiterated RatingBuy$31.00N/A
i
Rating by Ken Trbovich at Janney Montgomery Scott
10/4/2016Janney Montgomery ScottReiterated RatingBuy$28.00 ➝ $31.00N/A
i
Rating by Ken Trbovich at Janney Montgomery Scott
10/4/2016MizuhoDowngradeBuy ➝ NeutralN/A
i
Rating by Irina Rivkind Koffler at Mizuho
10/3/2016MizuhoDowngradeBuy ➝ Neutral$27.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
10/3/2016UBS GroupReiterated RatingNeutral$20.00 ➝ $26.00N/A
i
Rating by Ami Fadia at UBS Group AG
10/2/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Jason Gerberry at SVB Leerink LLC
9/28/2016Janney Montgomery ScottReiterated RatingBuy$28.00N/A
i
Rating by Ken Trbovich at Janney Montgomery Scott
9/23/2016Royal Bank of CanadaReiterated RatingSector Perform$22.00N/A
i
9/16/2016MizuhoBoost Price TargetBuy$23.00 ➝ $27.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
9/14/2016Janney Montgomery ScottReiterated RatingBuy$28.00N/A
i
Rating by Ken Trbovich at Janney Montgomery Scott
8/11/2016Cantor FitzgeraldReiterated RatingBuyN/A
i
Rating by Chiara Russo at Cantor Fitzgerald
8/4/2016Piper Jaffray CompaniesReiterated RatingNeutral$18.00 ➝ $19.00N/A
i
Rating by David Amsellem at Piper Jaffray Companies
8/4/2016JMP SecuritiesLower Price TargetMarket Outperform$28.00 ➝ $22.00N/A
i
8/4/2016Janney Montgomery ScottReiterated RatingBuy$28.00N/A
i
Rating by Ken Trbovich at Janney Montgomery Scott
8/4/2016MizuhoReiterated RatingBuy$23.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
7/28/2016Cantor FitzgeraldReiterated RatingBuy$26.00N/A
i
Rating by Chiara Russo at Cantor Fitzgerald
7/27/2016Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$21.00 ➝ $18.00N/A
i
7/21/2016MizuhoReiterated RatingPositiveN/A
i
Rating by Irina Rivkind Koffler at Mizuho
7/19/2016Cantor FitzgeraldReiterated RatingBuyN/A
i
Rating by Chiara Russo at Cantor Fitzgerald
7/18/2016Janney Montgomery ScottReiterated RatingBuy$28.00N/A
i
Rating by Ken Trbovich at Janney Montgomery Scott
7/18/2016SVB LeerinkReiterated RatingPositiveN/A
i
Rating by Jason Gerberry at SVB Leerink LLC
7/11/2016Royal Bank of CanadaReiterated RatingHoldN/A
i
Rating by Randall Stanicky at Royal Bank of Canada
7/8/2016Janney Montgomery ScottReiterated RatingBuy$28.00N/A
i
Rating by Ken Trbovich at Janney Montgomery Scott
7/7/2016UBS GroupDowngradeBuy ➝ Neutral$20.00N/A
i
Rating by Ami Fadia at UBS Group AG
6/26/2016MizuhoReiterated RatingBuyN/A
i
Rating by Irina Rivkind Koffler at Mizuho
6/22/2016Cantor FitzgeraldReiterated RatingBuyN/A
i
Rating by Chiara Russo at Cantor Fitzgerald
6/15/2016Janney Montgomery ScottReiterated RatingBuy$28.00N/A
i
Rating by Ken Trbovich at Janney Montgomery Scott
5/27/2016MizuhoBoost Price TargetBuy$19.00 ➝ $23.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
5/26/2016Janney Montgomery ScottBoost Price TargetNeutral ➝ Hold$20.13 ➝ $28.00N/A
i
Rating by Ken Trbovich at Janney Montgomery Scott
5/24/2016UBS GroupReiterated RatingBuy$20.00N/A
i
Rating by Ami Fadia at UBS Group AG
5/17/2016Janney Montgomery ScottReiterated RatingBuy$28.00N/A
i
Rating by Ken Trbovich at Janney Montgomery Scott
5/9/2016MizuhoUpgradeNeutral ➝ Buy$18.00 ➝ $19.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
5/8/2016MizuhoUpgradeNeutral ➝ Buy$18.00 ➝ $19.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
5/8/2016Cantor FitzgeraldReiterated RatingBuyN/A
i
Rating by Chiara Russo at Cantor Fitzgerald
5/6/2016Piper Jaffray CompaniesLower Price TargetOverweight$23.00 ➝ $21.00N/A
i
5/2/2016Royal Bank of CanadaReiterated RatingSector Perform$22.00N/A
i
Rating by Randall Stanicky at Royal Bank of Canada
4/26/2016Cantor FitzgeraldReiterated RatingBuy$26.00N/A
i
Rating by Chiara Russo at Cantor Fitzgerald
4/16/2016SVB LeerinkReiterated RatingOutperformN/A
i
Rating by Jason Gerberry at SVB Leerink LLC
4/12/2016Janney Montgomery ScottReiterated RatingBuy$28.00N/A
i
Rating by Ken Trbovich at Janney Montgomery Scott
4/11/2016MizuhoBoost Price TargetNeutral$14.00 ➝ $18.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
4/10/2016Cantor FitzgeraldReiterated RatingBuy$26.00N/A
i
Rating by Chiara Russo at Cantor Fitzgerald
4/9/2016MizuhoReiterated RatingNeutral$14.00 ➝ $18.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
3/29/2016SVB LeerinkReiterated RatingOutperformN/A
i
Rating by Jason Gerberry at SVB Leerink LLC
3/29/2016Cantor FitzgeraldReiterated RatingBuy$26.00N/A
i
Rating by Chiara Russo at Cantor Fitzgerald
3/28/2016Roth CapitalReiterated RatingBuyN/A
i
Rating by Scott Henry at Roth Capital
3/25/2016Royal Bank of CanadaLower Price Target$24.00 ➝ $22.00N/A
i
Rating by Randall Stanicky at Royal Bank of Canada
3/24/2016Piper Jaffray CompaniesReiterated RatingOverweight$23.00N/A
i
3/24/2016Northland SecuritiesInitiated CoverageOutperform$22.00N/A
i
3/24/2016MizuhoLower Price TargetNeutral$16.00 ➝ $14.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
3/10/2016SVB LeerinkReiterated RatingOutperformN/A
i
Rating by J. Gerberry at SVB Leerink LLC
3/10/2016SVB LeerinkInitiated CoverageOutperform$21.00N/A
i
(Data available from 3/2/2016 forward)
Depomed logo
Assertio Holdings, Inc. operates as a holding company. The firm develops pharmaceuticals. It engages in the provision of solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.
Read More

Today's Range

Now: $7.30
$7.09
$7.42

50 Day Range

MA: N/A

52 Week Range

Now: $7.30
$4.31
$9.48

Volume

940,193 shs

Average Volume

1,300,311 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Depomed?

The following equities research analysts have issued reports on Depomed in the last twelve months:
View the latest analyst ratings for DEPO.

What is the current price target for Depomed?

0 Wall Street analysts have set twelve-month price targets for Depomed in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Depomed in the next year.
View the latest price targets for DEPO.

What is the current consensus analyst rating for Depomed?

Depomed currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for DEPO.

What other companies compete with Depomed?

How do I contact Depomed's investor relations team?

Depomed's physical mailing address is 7999 GATEWAY BLVD. SUITE 300, NEWARK CA, 94560. The specialty pharmaceutical company's listed phone number is (224) 419-7106 and its investor relations email address is [email protected] The official website for Depomed is www.depomedinc.com.